GSK Enters Agreement to Acquire Nuvalent, Inc.

GSK plc has announced an agreement to acquire Nuvalent, Inc. for $10.6 billion. This strategic acquisition includes three lung cancer products: two late-stage inhibitors for ROS1 (zidesamtinib) and ALK (neladalkib) that are currently under US FDA review for 2026 approvals, and a third asset (NVL-330) in Phase I trials for HER2-altered NSCLC. The deal also encompasses Nuvalent's preclinical portfolio. This move is expected to accelerate GSK's entry into the lung cancer market, provide a platform for expansion with their B7-H3 antibody-drug conjugate (ADC), Ris-Rez, and be accretive to sales and operating profit starting in 2027. The acquisition is anticipated to be funded through debt facilities and cash, with no expected impact on GSK's credit rating. The transaction is subject to customary closing conditions, including shareholder approval and regulatory clearance. Financial advisors for GSK include Leerink Partners LLC and Citigroup Inc., with legal counsel from Davis Polk & Wardwell LLP and Slaughter and May.